FDA Inspection 1068986 — Central Pennsylvania Blood Bank Headquarters
The FDA completed an inspection of Central Pennsylvania Blood Bank Headquarters on Aug 14, 2018 in Hummelstown, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 14, 2018
- Fiscal Year
- 2018
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Hummelstown, PA (United States)